377sek
4,7 %
Date:2024-05-20Time:17:29:57Latest report:Q4-2023List:Small CapTicker:CANTA
Market Cap:693 msekEnterprise Value:498 msekNet Sales:- msekEarnings:-280,0 msekEmployees:0ISIN:SE0006371126

Ratios

10-year key figure history for Cantargia turnover, profit, dividend, equity, PE and PB.

Pre
Pre

Stockprice

Price movement for Cantargia with index and moving average MA50 and MA200.

Stockprice:3,77
MA50:3,46
MA200:3,74
Price/MA200:0,7 %
RSI (14):59,2
Price/MA50:9,1 %

Description

Cantargia AB is engaged in the development of products used in the treatment of cancer. It has developed specific antibodies against IL1RAP to treat serious, life-threatening diseases. The company's first product candidate, CAN04, has also been designed to treat different forms of cancer, with the initial focus on the treatment of non-small cell lung cancer and pancreatic cancer. The CAN10 project covers a disease segment that complements nadunolimab and diversifies Cantargia’s project portfolio.

Biotechnology